CITIUS ONCOLOGY, INC. (CTOR) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US17331Y1091

Price
0.57 USD
Market cap
60.68 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

CITIUS ONCOLOGY, INC. financials

Fiscal year2025
Operating income-23.52 m USD
EBIT-23.52 m USD
Net income-24.76 m USD
Diluted EPS – continuing operations-0.34 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.